People with monoclonal gammopathy of undetermined significance (MGUS) placed at low- or intermediate-risk of progression to multiple myeloma can develop that cancer within five…
KappaMab (MDX-1097), a new monoclonal antibody that binds to the kappa myeloma antigen, has a favorable safety profile in multiple myeloma patients with excess kappa…
The U.S. Food and Drug Administration (FDA) has lifted its hold on the CANOVA Phase 3 clinical trial, which is evaluating the experimental therapeutic…
Adding Darzalex (daratumumab) to the standard first-line treatment of Revlimid (lenalidomide) plus dexamethasone improves treatment and survival outcomes in multiple myeloma patients…
Isatuximab, a potential therapeutic antibody, can improve survival in relapsed/refractory multiple myeloma patients being given a standard treatment consisting of Pomalyst (pomalidomide) and…
A panel of blood markers that identifies tumors with more active blood vessels may help stratify multiple myeloma patients according to their risk, a study found.
Analysis of thousands of individual cells in multiple myeloma patients allows for a much more precise diagnosis — distinguishing asymptomatic, early-stage patients from those…